I'm really curious how the market is going to reac
Post# of 72440
Pros:
-We have completed the trial successfully with solid top line results.
-Now there is nothing stopping a Brilacidin deal of some kind now.
-Secondary endpoint data could be much stronger than top line.
-The bar is low for OM treatment.
Cons:
-The post-interim results of the trial appear to be notably worse than those presented at interim.
Am I off base with my conclusions? If so, please correct me. Feeling quite mixed about the results.
Go IPIX!